Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
AUTLAutolus(AUTL) Seeking Alpha·2024-09-07 02:12
kadirkaplan/iStock via Getty Images Investment Overview - Brife Cell Therapy Overview — Autolus' November PDUFA Date The list of approved cell therapies is growing every year, and potentially, Autolus Therapeutics plc (NASDAQ:AUTL), the United Kingdom based T-cell specialist could be the next to enter the commercial markets. As a reminder, “autologous” cell therapies work extraction a patients' cells, transportation to a lab, genetically engineer the cells to be able to target, attack and destroy, certa ...